Bravecto
fluralaner
Table of contents
Overview
Bravecto is a veterinary medicine used to treat parasitic infestations in dogs and cats. It may be used:
• to treat flea and tick infestations in dogs and cats;
• as part of the management of flea allergy dermatitis (an allergic reaction to flea bites) in dogs and cats;
• to treat demodectic and sarcoptic mange (skin infestation caused by two different mites) in dogs;
• to reduce the risk of infection with the parasite Babesia canis canis transmitted by Dermacentor reticulatus ticks in dogs;
• to treat ear mite infestations in cats.
Bravecto contains the active substance fluralaner.
Authorisation details
Product details | |
---|---|
Name |
Bravecto
|
Agency product number |
EMEA/V/C/002526
|
Active substance |
fluralaner
|
International non-proprietary name (INN) or common name |
fluralaner
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP53BE02
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International B.V
|
Revision |
17
|
Date of issue of marketing authorisation valid throughout the European Union |
11/02/2014
|
Contact address |
Wim de Körverstraat 35 |
Product information
01/02/2022 Bravecto - EMEA/V/C/002526 - II/0051
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Ectoparasiticides for systemic use
-
Isoxazolines
Therapeutic indication
Dogs:
- For the treatment of tick and flea infestations;
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- For the treatment of demodicosis caused by Demodex canis;
- For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.
- For reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus. [chewable tablets only]
Cats:
- For the treatment of tick and flea infestations;
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- For the treatment of infestations with ear mites (Otodectes cynotis).